Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
- PMID: 9360926
- DOI: 10.1126/science.278.5341.1291
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Abstract
In evaluating current combination drug regimens for treatment of human immunodeficiency virus (HIV) disease, it is important to determine the existence of viral reservoirs. After depletion of CD8 cells from the peripheral blood mononuclear cells (PBMCs) of both patients and normal donors, activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from PBMCs of six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years. Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.
Comment in
-
HIV survives drug onslaught by hiding out in T cells.Science. 1997 Nov 14;278(5341):1227. doi: 10.1126/science.278.5341.1227. Science. 1997. PMID: 9411749 No abstract available.
Similar articles
-
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.J Infect Dis. 1999 Aug;180(2):320-9. doi: 10.1086/314880. J Infect Dis. 1999. PMID: 10395845 Clinical Trial.
-
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.N Engl J Med. 1998 Oct 29;339(18):1261-8. doi: 10.1056/NEJM199810293391801. N Engl J Med. 1998. PMID: 9791141 Clinical Trial.
-
Prevalence and predictive value of intermittent viremia with combination hiv therapy.JAMA. 2001 Jul 11;286(2):171-9. doi: 10.1001/jama.286.2.171. JAMA. 2001. PMID: 11448280
-
Measuring HIV Persistence on Antiretroviral Therapy.Adv Exp Med Biol. 2018;1075:265-284. doi: 10.1007/978-981-13-0484-2_11. Adv Exp Med Biol. 2018. PMID: 30030797 Review.
-
Can HIV infection be eradicated through use of potent antiviral agents?Curr Opin Infect Dis. 2010 Dec;23(6):628-32. doi: 10.1097/QCO.0b013e32833ff1d0. Curr Opin Infect Dis. 2010. PMID: 20847693 Review.
Cited by
-
μ-Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies.FASEB J. 2020 Nov;34(11):14615-14630. doi: 10.1096/fj.202001612RR. Epub 2020 Sep 9. FASEB J. 2020. PMID: 32901981 Free PMC article.
-
Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA.Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18692-18700. doi: 10.1073/pnas.2006816117. Epub 2020 Jul 20. Proc Natl Acad Sci U S A. 2020. PMID: 32690683 Free PMC article.
-
Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir.Elife. 2020 Sep 29;9:e60933. doi: 10.7554/eLife.60933. Elife. 2020. PMID: 32990219 Free PMC article.
-
Human Immunodeficiency Virus 1 (HIV-1): Viral Latency, the Reservoir, and the Cure.Yale J Biol Med. 2020 Sep 30;93(4):549-560. eCollection 2020 Sep. Yale J Biol Med. 2020. PMID: 33005119 Free PMC article. Review.
-
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.PLoS One. 2012;7(3):e31990. doi: 10.1371/journal.pone.0031990. Epub 2012 Mar 1. PLoS One. 2012. PMID: 22396745 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials